Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

705 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The complex landscape of luminal breast cancer.
Lutz C, Messal HA, Vareslija D, Prekovic S. Lutz C, et al. Endocr Relat Cancer. 2024 Dec 19;32(1):e240201. doi: 10.1530/ERC-24-0201. Print 2025 Jan 1. Endocr Relat Cancer. 2024. PMID: 39498702 Review.
A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.
Hutten SJ, de Bruijn R, Lutz C, Badoux M, Eijkman T, Chao X, Ciwinska M, Sheinman M, Messal H, Herencia-Ropero A, Kristel P, Mulder L, van der Waal R, Sanders J, Almekinders MM, Llop-Guevara A, Davies HR, van Haren MJ, Martin NI, Behbod F, Nik-Zainal S, Serra V, van Rheenen J, Lips EH, Wessels LFA; Grand Challenge PRECISION Consortium; Wesseling J, Scheele CLGJ, Jonkers J. Hutten SJ, et al. Among authors: lutz c. Cancer Cell. 2023 May 8;41(5):986-1002.e9. doi: 10.1016/j.ccell.2023.04.002. Epub 2023 Apr 27. Cancer Cell. 2023. PMID: 37116492 Free PMC article.
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
Prekovic S, Chalkiadakis T, Roest M, Roden D, Lutz C, Schuurman K, Opdam M, Hoekman L, Abbott N, Tesselaar T, Wajahat M, Dwyer AR, Mayayo-Peralta I, Gomez G, Altelaar M, Beijersbergen R, Győrffy B, Young L, Linn S, Jonkers J, Tilley W, Hickey T, Vareslija D, Swarbrick A, Zwart W. Prekovic S, et al. Among authors: lutz c. EMBO Mol Med. 2023 Dec 7;15(12):e17737. doi: 10.15252/emmm.202317737. Epub 2023 Oct 30. EMBO Mol Med. 2023. PMID: 37902007 Free PMC article.
Rat Models of Hormone Receptor-Positive Breast Cancer.
Nicotra R, Lutz C, Messal HA, Jonkers J. Nicotra R, et al. Among authors: lutz c. J Mammary Gland Biol Neoplasia. 2024 Jun 24;29(1):12. doi: 10.1007/s10911-024-09566-0. J Mammary Gland Biol Neoplasia. 2024. PMID: 38913216 Free PMC article. Review.
Mechanisms that clear mutations drive field cancerization in mammary tissue.
Ciwinska M, Messal HA, Hristova HR, Lutz C, Bornes L, Chalkiadakis T, Harkes R, Langedijk NSM, Hutten SJ, Menezes RX, Jonkers J, Prekovic S; Grand Challenge PRECISION consortium; Simons BD, Scheele CLGJ, van Rheenen J. Ciwinska M, et al. Among authors: lutz c. Nature. 2024 Sep;633(8028):198-206. doi: 10.1038/s41586-024-07882-3. Epub 2024 Sep 4. Nature. 2024. PMID: 39232148 Free PMC article.
Emerging roles of cohesin-STAG2 in cancer.
Scott JS, Al Ayadi L, Epeslidou E, van Scheppingen RH, Mukha A, Kaaij LJT, Lutz C, Prekovic S. Scott JS, et al. Among authors: lutz c. Oncogene. 2025 Feb;44(5):277-287. doi: 10.1038/s41388-024-03221-y. Epub 2024 Nov 29. Oncogene. 2025. PMID: 39613934 Review.
Large-Scale Characterization of Orthotopic Cell Line-Derived Xenografts Identifies TGF-β Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness.
Lutz C, Chao X, de Klein B, Bhin J, Badoux M, Eijkman T, Nikolakopoulos AP, Hutten SJ, Proost N, Siteur B, van de Ven M, Song JY, van Rheenen J, Morgner J, Prekovic S, Jonkers J. Lutz C, et al. Cancer Res. 2025 Apr 30. doi: 10.1158/0008-5472.CAN-24-2022. Online ahead of print. Cancer Res. 2025. PMID: 40305101
Correction: Emerging roles of cohesin-STAG2 in cancer.
Scott JS, Al Ayadi L, Epeslidou E, van Scheppingen RH, Mukha A, Kaaij LJT, Lutz C, Prekovic S. Scott JS, et al. Among authors: lutz c. Oncogene. 2025 Jun 20. doi: 10.1038/s41388-025-03479-w. Online ahead of print. Oncogene. 2025. PMID: 40542201 No abstract available.
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.
Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, Bhattacharya A, Joosten SEP, Da Silva AM, Padrao N, Wellenstein MD, Kersten K, de Boo M, Roorda M, Henneman L, de Bruijn R, Annunziato S, van der Burg E, Drenth AP, Lutz C, Endres T, van de Ven M, Eilers M, Wessels L, de Visser KE, Zwart W, Fehrmann RSN, van Vugt MATM, Jonkers J. Zimmerli D, et al. Among authors: lutz c. Nat Commun. 2022 Nov 2;13(1):6579. doi: 10.1038/s41467-022-34000-6. Nat Commun. 2022. PMID: 36323660 Free PMC article.
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B, van Gerwen B, de Bruijn R, van Miltenburg MH, Huijbers IJ, van de Ven M, Visvader JE, Lindeman GJ, Wessels LFA, Jonkers J. Annunziato S, et al. Among authors: lutz c. Nat Commun. 2019 Jan 23;10(1):397. doi: 10.1038/s41467-019-08301-2. Nat Commun. 2019. PMID: 30674894 Free PMC article.
705 results